China has been engaged in the R&D and manufacturing of semi-automatic coagulation analyzers for over a decade, and based on the data from the website of the NMPA, in 2024 and 2025 (as od 15 August), a total of 2 instruments from 2 manufacturers have obtained registration certificates...

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China. Latest news

The US Food and Drug Administration released a notice on Thursday that Meridian Biosciences' Revogene SARS-CoV-2 test is unlikely to be able to detect the Omicron variant.

Qiagen and Denovo Biopharma said on Thursday that they are collaborating to develop a blood-based companion diagnostic test to identify patients expressing a genomic biomarker who are likely to respond to Denovo's investigational DB102 treatment for diffuse large B-cell lymphoma.

Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.

On December 8, Roche Diagnostics China (hereinafter referred to as "Roche") and SHAPHAR announced the opening of a new round of strategic cooperation.

A potentially game-changing Antigen Rapid Test (ART) technology to diagnose COVID-19 has been developed by scientists in Singapore.

Thermo Fisher Scientific said on Thursday that the US Food and Drug Administration has granted premarket approval to the company's Oncomine Dx Target Test as a companion diagnostic for Janssen Biotech's targeted lung cancer treatment amivantamab-vmjw (Rybrevant).

Dec. 8, 2021 -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.

UK molecular diagnostics company Genedrive said on Wednesday that its rapid molecular COVID-19 test has received CE marking.

To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or organ, for example, or to one kind of microbe growing in a test tube.

Since December 2019, the epidemic has raged all over the world. Affected by the epidemic, more than 1,400 China in vitro diagnostic companies are facing severe challenges. As of the end of November, 24 IVD-related companies have been successfully listed during the epidemic.